C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/rccm.201006-0905OCPMID 21471108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spatial and temporal patterns of c-kit positive cells in embryonic lungs

  2011cited by this paper
• Prevention of Mast Cell Degranulation by Disodium Cromoglycate Delayed the Regression of Hypoxic Pulmonary Hypertension in Rats

  2010cited by this paper
• Long Term Use Of Imatinib In Patients With Severe Pulmonary Arterial Hypertension

  2010cited by this paper
• Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall.

  2009cited by this paper
• Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension.

  2009cited by this paper
• Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1.

  2009cited by this paper
• Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

  2008cited by this paper
• Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats.

  2008cited by this paper
• Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension

  2008cited by this paper
• Prevention of Mast Cell Degranulation by Disodium Cromoglycate Attenuates the Development of Hypoxic Pulmonary Hypertension in Rats Exposed to Chronic Hypoxia

  2008cited by this paper
• Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Emerging functions of c-kit and its ligand stem cell factor in dendritic cells

  2008cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

  2008cited by this paper
• Depletion of endothelial progenitor cells may link pulmonary fibrosis and pulmonary hypertension.

  2007cited by this paper
• Role of mast cells in airway remodeling.

  2007cited by this paper
• Diverse Contribution of Bone Marrow-Derived Cells to Vascular Remodeling Associated With Pulmonary Arterial Hypertension and Arterial Neointimal Formation

  2007cited by this paper
• Mast cells in the promotion and limitation of chronic inflammation

  2007cited by this paper
• Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

  2007cited by this paper
• Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension

  2007cited by this paper
• Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.

  2006cited by this paper
• Role of Circulating Vascular Progenitors in Angiogenesis, Vascular Healing, and Pulmonary Hypertension: Lessons From Animal Models

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• Pulmonary arterial hypertension in France: results from a national registry.

  2006cited by this paper
• Reduced exercise capacity in a mouse model of asthma

  2006cited by this paper
• Long term imatinib treatment in pulmonary arterial hypertension.

  2006cited by this paper
• KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Imatinib for the treatment of pulmonary arterial hypertension.

  2005cited by this paper
• Treatment of pulmonary arterial hypertension.

  2004cited by this paper
• Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.

  2004cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• Pathologic assessment of vasculopathies in pulmonary hypertension.

  2004cited by this paper
• Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure

  2003cited by this paper
• Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis

  2002cited by this paper
• Mobilized bone marrow cells repair the infarcted heart, improving function and survival

  2001cited by this paper
• Serum-soluble c-kit levels during mobilization of peripheral blood stem cells correlate with stem cell yield.

  2000cited by this paper
• Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.

  1999cited by this paper
• Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

  1999cited by this paper
• Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease.

  1999cited by this paper
• Mast cell chymase in pulmonary hypertension

  1999cited by this paper
• Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines.

  1995cited by this paper
• Soluble kit receptor in human serum.

  1995cited by this paper
• Epitope mapping and functional studies with three monoclonal antibodies to the C‐KIT receptor tyrosine kinase, YB5.B8, 17F11, and SR‐1

  1994cited by this paper
• Lung mast cells in plexogenic pulmonary arteriopathy.

  1991cited by this paper
• Expression and function of c-kit in hemopoietic progenitor cells

  1991cited by this paper
• Monoclonal antibody YB5.B8 identifies the human c-kit protein product

  1991cited by this paper
• Monoclonal antibody YB5.B8 identifies the human c-kit protein product.

  1991cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper
• Copyright © American Society for Investigative Pathology DOI: 10.2353/ajpath.2008.070705 Cardiovascular, Pulmonary and Renal Pathology Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension

  year unknowncited by this paper

• Deciphering the Counterintuitive Role of Vascular Endothelial Growth Factor Signaling Pathways in Pulmonary Arterial Hypertension

  2026cites this paper
• Vascular Remodeling: The Multicellular Mechanisms of Pulmonary Hypertension

  2025cites this paper
• Antiproliferative therapies in pulmonary arterial hypertension

  2025cites this paper
• Drugs targeting novel pathways in pulmonary arterial hypertension

  2025cites this paper
• Differentiation of lung tissue-resident c-Kit+ cells into microvascular endothelial cells alleviates pulmonary vascular remodeling.

  2025cites this paper
• Flow Cytometric Determination of Circulating Progenitor Cells in Patients With Pulmonary Arterial Hypertension: A Systematic Review

  2025cites this paper
• Cross-pollination of two specialties: potential repurposing of cancer and cardiovascular drugs for the benefit of the other.

  2025cites this paper
• Dysfunction in mitochondrial electron transport chain drives the pathogenesis of pulmonary arterial hypertension: insights from a multi-omics investigation

  2025cites this paper
• BMP9 regulates the endothelial secretome to drive pulmonary hypertension

  2025cites this paper
• Anti-remodeling therapies in pulmonary arterial hypertension.

  2025cites this paper
• Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study

  2025cites this paper
• Another Act in the Story of Oral Imatinib for Pulmonary Arterial Hypertension

  2025cites this paper
• Dysregulated VEGF/VEGFR-2 Signaling and Plexogenic Lesions in the Embryonic Lungs of Chickens Predisposed to Pulmonary Arterial Hypertension

  2024cites this paper
• Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

  2024cites this paper
• Extracellular purines in lung endothelial permeability and pulmonary diseases

  2024cites this paper
• Extrapulmonary manifestations of pulmonary arterial hypertension

  2024cites this paper
• Recent developments in connective tissue disease associated pulmonary arterial hypertension

  2024cites this paper
• Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.

  2024cites this paper
• Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension

  2024cites this paper
• Targeting IL‐11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension‐associated lung fibrosis

  2024cites this paper
• IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension

  2024cites this paper
• Role of Optical Coherence Tomography in Vasculitis-Associated Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension.

  2024cites this paper
• Mast cells are at the interface between the external environment and the inner organism

  2024cites this paper
• Pulmonary Vascular Remodeling in Pulmonary Hypertension

  2023cites this paper
• Perivascular inflammatory cells and their association with pulmonary arterial remodelling in dogs with pulmonary hypertension due to myxomatous mitral valve disease

  2023cites this paper
• Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling

  2023cites this paper
• Isolation of vasa vasorum endothelial cells from pulmonary artery adventitia: Implementation to vascular biology research.

  2023cites this paper
• Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension

  2023influential citation
• Pulmonary arterial hypertension.

  2023cites this paper
• Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

  2023cites this paper
• Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension

  2023cites this paper
• Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension

  2023cites this paper
• Pulmonary arterial hypertension in children with congenital heart disease: a deeper look into the role of endothelial progenitor cells and circulating endothelial cells to assess disease severity

  2023cites this paper
• Further explorations into the role of mast cells in deaths associated with fatal asphyxia: an immunohistochemical study utilizing CD 117 marker.

  2023cites this paper
• Hub Genes and Immune Cell Infiltration in Hypoxia-Induced Pulmonary Hypertension: Bioinformatics Analysis and In Vivo Validation.

  2023cites this paper
• Immunity and Inflammation in Pulmonary Arterial Hypertension: From Pathophysiology Mechanisms to Treatment Perspective.

  2022cites this paper
• AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

  2022cites this paper
• Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension

  2022cites this paper
• Early View

  2022cites this paper
• Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling

  2022cites this paper
• Tm4sf1-marked Endothelial Subpopulation Is Dysregulated in Pulmonary Arterial Hypertension.

  2022cites this paper
• G6PD is a critical enabler of hypoxia-induced accumulation of macrophages and platelets in mice lungs and contributor to lung inflammation.

  2022cites this paper
• On vasa vasorum: A history of advances in understanding the vessels of vessels

  2022cites this paper
• Potential contribution of early endothelial progenitor cell (eEPC)-to-macrophage switching in the development of pulmonary plexogenic lesion

  2022cites this paper
• Autoimmunity in Pulmonary Arterial Hypertension: Evidence for Local Immunoglobulin Production

  2021cites this paper
• Identification of Potential Biomarkers and Immune Infiltration Characteristics in Idiopathic Pulmonary Arterial Hypertension Using Bioinformatics Analysis

  2021cites this paper
• Meticulous closure of collateral vessels in the perihilar mediastinal pleura to control intraoperative bleeding during lung transplantation for pulmonary hypertension

  2021cites this paper
• TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension

  2021cites this paper
• Adventitial and Skeletal Muscle Pericytes in Health and Ischemic Tissue Regeneration

  2021cites this paper
• Cell tracking suggests pathophysiological and therapeutic role of bone marrow cells in Sugen5416/hypoxia rat model of pulmonary arterial hypertension.

  2021cites this paper
• Inhibition of CXCR4 ameliorates hypoxia-induced pulmonary arterial hypertension in rats.

  2021cites this paper
• Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension

  2021cites this paper
• Inhibition of immunoglobulin E attenuates pulmonary hypertension

  2021cites this paper
• Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy

  2021cites this paper
• Pulmonary arterial hypertension (PAH) from autopsy study: T-cells, B-cells and mastocytes detection as morphological evidence of immunologically mediated pathogenesis.

  2021cites this paper
• Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune‐mediated diseases

  2021cites this paper
• Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

  2021cites this paper
• Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.

  2021cites this paper
• Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.

  2020cites this paper
• Stem/Progenitor Cells and Pulmonary Arterial Hypertension.

  2020cites this paper
• Perivascular Inflammation in Pulmonary Arterial Hypertension

  2020cites this paper
• Identification of Differentially Expressed Genes Associated with Idiopathic Pulmonary Arterial Hypertension by Integrated Bioinformatics Approaches

  2020cites this paper
• c-Jun, Foxo3a, and c-Myc Transcription Factors are Key Regulators of ATP-Mediated Angiogenic Responses in Pulmonary Artery Vasa Vasorum Endothelial Cells

  2020cites this paper
• Pluripotent hematopoietic stem cells augment (cid:2) -adrenergic receptor-mediated contraction of pulmonary artery and contribute to the pathogenesis of pulmonary hypertension

  2020cites this paper
• The Hallmarks of Severe Pulmonary Arterial Hypertension: The Cancer Hypothesis - Ten years later.

  2020cites this paper
• Pluripotent HSCs Augment a-Adrenergic Receptor-Mediated Contraction of Pulmonary Artery and Contribute to the Pathogenesis of Pulmonary Hypertension.

  2020cites this paper
• Clonally selected primitive endothelial cells promote occlusive pulmonary arteriopathy and severe pulmonary hypertension in rats exposed to chronic hypoxia

  2020cites this paper
• Potential mechanisms and serum biomarkers involved in sex differences in pulmonary arterial hypertension

  2020cites this paper
• Explant culture: A relevant tool for the study of telocytes

  2020cites this paper
• The Multiple Roles of Macrophage Migration Inhibitory Factor in Pulmonary Hypertension.

  2020influential citation
• Vascularization of the arteriovenous fistula wall and association with maturation outcomes

  2019cites this paper
• Angiogenesis in Pulmonary Arterial Hypertension-Imaging of the Right Heart in a New Mouse Model

  2019cites this paper
• KIT as a therapeutic target for non‐oncological diseases

  2019cites this paper
• Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

  2019cites this paper
• Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.

  2019cites this paper
• Low dose 100 cGy irradiation as a potential therapy for pulmonary hypertension

  2019cites this paper
• TCRM_A_219024 1427..1442

  2019cites this paper
• Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure

  2019cites this paper
• Chronic Inflammation Within the Vascular Wall in Pulmonary Arterial Hypertension: More than a Spectator.

  2019cites this paper
• Endothelial cells are a source of Nestin expression in Pulmonary Arterial Hypertension

  2019cites this paper
• Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH)

  2019cites this paper
• Involvement of immune responses in pulmonary arterial hypertension; lessons from rodent models

  2019cites this paper
• Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

  2018cites this paper
• Pulmonary Hypertension Induced by Anticancer Drugs

  2018cites this paper
• Bone Marrow–Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism

  2018cites this paper
• Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.

  2018cites this paper
• Blood Outgrowth and Proliferation of Endothelial Colony Forming Cells are Related to Markers of Disease Severity in Patients with Pulmonary Arterial Hypertension

  2018cites this paper
• Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension

  2018cites this paper
• Characterization, localization and comparison of c-Kit+ lung cells in never smokers and smokers with and without COPD

  2018cites this paper
• GPCRs in pulmonary arterial hypertension: tipping the balance

  2018cites this paper
• Expression of AMHR2 and C-KIT in cervical lesions in Uyghur Women of Xinjiang, China

  2018cites this paper
• Long-term effect of low-dose imatinib therapy for pulmonary hypertension due to chronic degenerative mitral valve disease in six dogs

  2018cites this paper
• AMD3100 treatment attenuates pulmonary angiogenesis by reducing the c-kit (+) cells and its pro-angiogenic activity in CBDL rat lungs.

  2018cites this paper
• Oxidized phospholipids stimulate production of stem cell factor via NRF2-dependent mechanisms

  2018cites this paper
• The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not

  2018cites this paper
• Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension

  2018cites this paper
• The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension

  2018cites this paper
• Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study

  2017cites this paper
• Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity.

  2017cites this paper
• Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis

  2017cites this paper